PedAM
Pediatric Disease Annotations & Medicines
| Disease | cystic fibrosis |
| Phenotype | C0004096|bronchial asthma |
| Sentences | 1 |
| PubMedID- 23204847 | Since 2001, omalizumab (xolair, genentech, novartis, south san francisco, ca) has been a useful treatment for moderate to severe allergic asthma, but limited literature exists on its use in abpa with bronchial asthma in patients without cystic fibrosis (cf).6–8 in 2007, we presented preliminary data on three patients with treatment-resistant abpa (ie, those with corticosteroid-dependent disease), who were treated with omalizumab with improvement regarding quality of life symptoms, medication usage and pulmonary function testing.9 recently, case reports of patients with cystic fibrosis and abpa and adult asthmatics with abpa have suggested that omalizumab, a recombinant anti-immunoglobulin e, might be effective for treating acute exacerbations and reducing systemic corticosteroid requirements.7–13 we sought to clarify whether omalizumab is a useful adjunctive therapy for adult asthmatics with abpa. |
Page: 1